A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

NCT06898255 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Cachexia

Interventions

DRUG: GFS202A injection

Sponsor

Genfleet Therapeutics (Shanghai) Inc.